Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.62 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.51 |
| ▸ | TUBB | P07437 | 1/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14407961 | 0.84 | HTR7 (0.68) | KITEGFRHTR7CSF1RACHE | |
| SCHEMBL27761143 | 0.81 | HRH4 (0.61) | KDM4EMAPTMAPK1NPSR1KIT | |
| Hydrochloric Acid SCHEMBL6159628 | 0.80 | NUDT1 (0.51) | KDM4EMAPTMAPK1NPSR1DRD1 | |
| Hydrochloric Acid SCHEMBL9270707 | 0.79 | HRH4 (0.60) | KDM4EMAPTMAPK1NPSR1KIT | |
| SCHEMBL4399140 | 0.79 | HTR7 (0.64) | KITEGFRPDGFRBHTR7CSF1R | |
| SCHEMBL10072150 | 0.77 | ENPP1 (0.49) | KDM4EMAPTMAPK1NPSR1KIT | |
| SCHEMBL8649684 | 0.77 | EGFR (0.52) | KDM4EMAPTMAPK1NPSR1KIT | |
| SCHEMBL10072172 | 0.77 | KDM4E (0.64) | KDM4EMAPTMAPK1NPSR1PDGFRB | |
| SCHEMBL14820346 | 0.76 | GAK (0.68) | KDM4EMAPK1KITPDGFRBALDH1A1 | |
| SCHEMBL27339218 | 0.76 | MAPK1 (0.62) | KDM4EMAPTMAPK1NPSR1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723134-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | Pfizer Products Incorporated (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | claimed |
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2005-08-18 | — | — | US | claimed |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PFIZER INC. | 2009-06-25 | — | — | US | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1755611-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1723134-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | Pfizer Products Incorporated (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005120514-A1 | PHOSPHODIESTERASE 10 INHIBITION AS TREATMENT FOR OBESITY-RELATED AND METABOLIC SYNDROME-RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005082883-A2 | TETRAHYDROISOQUINOLINYL DERIVATIVES OF QUINAZOLINE AND ISOQUINOLINE | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182079-A1 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PDE5A, PDE3A, PDE3B | KDM4E 1096/4885MAPT 1417/4885MAPK1 2380/4885 |
| US-20090162286-A1 | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions | PDE5A, PDE12, PDE2A | KDM4E 2074/4885MAPT 3848/4885MAPK1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.